1984 Volume 32 Issue Supplement4 Pages 272-280
Antibacterial activity, pharmacokinetics and clinical efficacy of SBT/CPZ were investigated, with the following results.
1. Antibacterial activities of SBT/CPZ against clinically isolated S.aureus, E. coli, K. pneumoniae, P. mirabilis and P. aeruginosa, each 50 strains, were about equal to those of CPZ. However, the sensitivity of the strains among E. coli, K. p neumoniae and P. mirabilis with MICs of more than 3.13-6.25μg/ml to CPZ was augmented by SBT/CPZ, demonstrating the usefulness to add the β-lactamase inhibitor.
2. SBT/CPZ 2g, was administered to 2 cases of respiratory tract infection by drip-infusion for 2 hours, and blood levels of each drug were monitored. The peak values were observed at the end of drip-infusion, and were 131.6 and 141.2μg/ml for CPZ, 58.2 and 60.3μg/ml for SBT, respectively.
The ratio of CPZ to SBT in blood was approximately 2: 1.
3. Three patients, one each of Klebsiella pneumonia, P. aeruginosa pulmonary abscess and chronic pyelonephritis, were treated with SBT/CPZ.
For the patient with Klebsiella pneumonia, SBT/CPZ at 2g/day was ineffective, but by increasing the does to 4.0g/day marked improvement was observed. For the patient with P. aeruginosa pulmonary abscess to whom CPZ was ineffective, the treatment with SBT/CPZ at 4g/day brought on a good result. In a case of chronic pyelonephritis caused by Klebsiella, the treatment with SBT/CPZ at 4.0g/day, but not 2.0g/day, resulted in improvement. From the above results, the dose of SBT/CPZ at 4.0g/day will be adequate for the treatment of relatively severe cases.
No adverse reactions or abnormal values of clinical chemistry by SBT/CPZ were observed.
